- Home
- IMAB vs SLS Comparison
IMAB vs SLS Comparison
Compare IMAB & SLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMAB
- SLS
- Stock Information
- Founded
- IMAB 2014
- SLS 2012
- Country
- IMAB United States
- SLS United States
- Employees
- IMAB N/A
- SLS N/A
- Industry
- IMAB Biotechnology: Pharmaceutical Preparations
- SLS Biotechnology: Pharmaceutical Preparations
- Sector
- IMAB Health Care
- SLS Health Care
- Exchange
- IMAB Nasdaq
- SLS Nasdaq
- Market Cap
- IMAB 83.8M
- SLS 75.3M
- IPO Year
- IMAB 2020
- SLS N/A
- Fundamental
- Price
- IMAB $0.94
- SLS $0.90
- Analyst Decision
- IMAB Strong Buy
- SLS
- Analyst Count
- IMAB 3
- SLS 0
- Target Price
- IMAB $8.00
- SLS N/A
- AVG Volume (30 Days)
- IMAB 288.7K
- SLS 1.6M
- Earning Date
- IMAB 08-28-2024
- SLS 11-13-2024
- Dividend Yield
- IMAB N/A
- SLS N/A
- EPS Growth
- IMAB N/A
- SLS N/A
- EPS
- IMAB N/A
- SLS N/A
- Revenue
- IMAB $3,313,984.00
- SLS N/A
- Revenue This Year
- IMAB N/A
- SLS N/A
- Revenue Next Year
- IMAB N/A
- SLS N/A
- P/E Ratio
- IMAB N/A
- SLS N/A
- Revenue Growth
- IMAB N/A
- SLS N/A
- 52 Week Low
- IMAB $0.90
- SLS $0.50
- 52 Week High
- IMAB $2.54
- SLS $1.72
- Technical
- Relative Strength Index (RSI)
- IMAB 38.29
- SLS 30.01
- Support Level
- IMAB $0.91
- SLS $0.86
- Resistance Level
- IMAB $1.11
- SLS $0.98
- Average True Range (ATR)
- IMAB 0.07
- SLS 0.11
- MACD
- IMAB -0.00
- SLS -0.02
- Stochastic Oscillator
- IMAB 13.01
- SLS 21.74
About IMAB I-MAB
I-MAB is a clinical-stage biotech company. Along with its subsidiaries, it is principally engaged in discovering and developing transformational biologics in the fields of immuno-oncology and immuno-inflammation diseases in the People's Republic of China and other countries and regions. Its drug pipeline includes Uliledlimab (TJD5) which is an antibody for solid tumors, Ragistomig (TJ-L14B), and Givastomig (TJ-CD4B).
About SLS SELLAS Life Sciences Group Inc.
SELLAS Life Sciences Group Inc is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's product candidates currently include galinpepimut-S, or GPS, a peptide immunotherapy directed against the Wilms tumor 1, or WT1, antigen, and GFH009, a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.